Zogenix (ZGNX) delivered earnings and revenue surprises of 5.88% and -6.18%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/06 02:15
Zogenix EPS beats by $0.04, beats on revenue
Zogenix (NASDAQ:ZGNX): Q2 GAAP EPS of -$0.96 beats by $0.04. Revenue of $1.03M (-3.7% Y/Y) beats by $0.48M. Press Release
seekingalpha · 08/06 01:13
Zogenix Provides Corporate Update and Reports Second Quarter 2020 Financial Results
* FINTEPLA® (fenfluramine) in Dravet syndrome is now FDA approved and commercially launched in the U.S. * More than 230 prescribers have already completed FINTEPLA REMS enrollment and certification * FDA meeting scheduled in September to discuss pla
GlobeNewswire · 08/05 20:01
Zogenix to Release Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 5
EMERYVILLE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and six months ended June 30, 2020, a
GlobeNewswire · 07/29 12:00
Earnings Preview: Zogenix (ZGNX) Q2 Earnings Expected to Decline
Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/28 16:33
Zogenix: A Critical Launch
Seeking Alpha - Article · 07/06 11:58
Zogenix's Long-Awaited Drug Approved With a Warning
Seizure medication must have black box warning due to safety issues Continue reading...